Gilead Gives Up On Galapagos's Filgotinib In RA
Belgian Biotech's Stock Battered
Executive Summary
A disappointing meeting with the FDA means "we no longer see a viable path to US approval in this indication,” said Gilead CEO Daniel O'Day, as Galapagos assumes sole responsibility for the commercialization of the JAK inhibitor in Europe.
You may also be interested in...
Galapagos Puts Faith In Refocused Pipeline To Regain Investor Confidence
The Belgian biotech's president, Bart Filius, tells Scrip that exiting the metabolic disease and osteoarthritis space and focusing on inflammation makes sense to "bring a bit more balance in terms of risk into our portfolio."
MANTA Brings Glimmer Of Good News To Galapagos
After a difficult spell for the Belgian biotech, positive interim data from two key studies looking at testicular toxicity concerns over filgotinib suggest a pathway for potential future US approval of the Gilead-partnered JAK inhibitor for IBD.
Jyseleca European Launches Could Lift Gloom At Galapagos
The Belgian biotech is pleased with the launch of its rheumatoid arthritis drug in Germany and the Netherlands and it has also secured a broad label from NICE.